Company intelligence / Profile preview

NeoMedLight

Ownership: Private
Development stage: Other

Overview

NeoMedLight has commercialized Bilicocoon for neonatal jaundice in 30 countries and CareMin650™ for the prevention and treatment of oral mucositis and radiation dermatitis. Clinical results from the Safe PBM study support efficacy in these indications. The company is expanding into other specialty wound care areas.

Therapeutic areas: DermatologyGastroenterologyOncology
Modalities: DevicePhotobiomodulation therapy (PBM)
Industry: Therapeutic Medical Devices

Partnerships

European Commission/Horizon2020 grant partnersRoseUp associationOncology Imaging Systems distribution partnership in the UK/Ireland

Beyond the preview

Go deeper on NeoMedLight.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NeoMedLight.

Explore the full profile